Ignite Creation Date:
2024-05-06 @ 3:41 PM
Last Modification Date:
2024-10-26 @ 1:55 PM
Study NCT ID:
NCT04723953
Status:
COMPLETED
Last Update Posted:
2022-10-25
First Post:
2021-01-22
Brief Title:
Cardiac Fibroblast Activation Detected by 68Ga-FAPI PETMR
Sponsor:
Ruijin Hospital
Organization:
Ruijin Hospital
Study Overview
Official Title:
Cardiac Fibroblast Activation Detected by 68Ga-FAPI PETMR is a Prognostic Indicator in Patients With Myocardial Infarction
Status:
COMPLETED
Status Verified Date:
2022-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Myocardial infarction is the most common cause of high mortality in the modern world The short-term survival rate of ST-elevated myocardial infarction STEMI has been dramatically increased in the past decades thanks to primary coronary intervention and standardization of treatment However the long-term prognosis of patients with acute myocardial infarction AMI is still poor especially in the aging population due to heart failure related to inappropriate myocardial fibrosis and subsequent left ventricular LV remodeling Despite the amelioration of STEMI management LV remodeling still occurs in approximately 13 of all STEMI patients Therefore early identification of such patients may help the optimization of therapy and eventually the outcomes
One characteristic of activated cardiac fibroblasts is the expression of FAP fibroblast activation protein A tracer FAP inhibitor for positron emission tomography that targets FAP has been used to measure relative FAP density indicative of activated fibroblasts in different cancer entities However whether it can reliably assess myocardial fibrosis and predict the poor prognosis caused by LV remodeling is not yet known Therefore We aim to observe active myocardial fibrosis process in patients with AMI and analyze its relationship with the patientsprognosis in a longitudinal study through 68Ga-FAPI PETMRI
One characteristic of activated cardiac fibroblasts is the expression of FAP fibroblast activation protein A tracer FAP inhibitor for positron emission tomography that targets FAP has been used to measure relative FAP density indicative of activated fibroblasts in different cancer entities However whether it can reliably assess myocardial fibrosis and predict the poor prognosis caused by LV remodeling is not yet known Therefore We aim to observe active myocardial fibrosis process in patients with AMI and analyze its relationship with the patientsprognosis in a longitudinal study through 68Ga-FAPI PETMRI
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None